Is MOTS-c Legal in Tennessee?

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 21-amino-acid peptide encoded within mitochondrial DNA. Unlike most peptides, it does not originate from nuclear DNA. Researchers first characterized it in a 2015 paper by Lee et al. Published in Cell Metabolism, which showed that MOTS-c improved insulin sensitivity and reduced obesity in mouse models fed a high-fat diet. (1)

Because it is biologically derived and structurally novel, MOTS-c sits in a regulatory space that does not fit neatly into FDA's existing drug-approval categories. That ambiguity matters enormously for Tennessee patients and prescribers.

Why the Source of a Peptide Affects Its Legal Category

FDA distinguishes between approved drugs, investigational drugs under an IND (Investigational New Drug) application, and bulk drug substances used in compounding. MOTS-c has never received an NDA (New Drug Application) approval. It has not completed Phase 3 trials in any indication. That means it cannot be legally marketed or sold as a finished pharmaceutical product in the United States without violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). (2)

Mitochondrial Origin: A Scientific Distinction That Regulators Have Not Fully Addressed

The fact that MOTS-c is mitochondria-derived rather than nuclear-gene-derived is scientifically interesting. No federal or Tennessee statute specifically creates a separate legal category for mitochondria-derived peptides. From a regulatory standpoint, FDA treats it the same way it treats any other peptide bulk substance: either it is on the approved compounding list, or it is not.

Federal Framework: FDA Bulk Drug Substances and the 503A/503B Rules

The legal foundation for any compounded peptide in the United States runs through two sections of the FD&C Act: Section 503A (traditional compounding pharmacies) and Section 503B (outsourcing facilities). Understanding this framework is the first step to understanding whether a Tennessee patient can legally obtain MOTS-c.

Section 503A: Traditional Compounding Pharmacies

Under 503A, a licensed pharmacist or physician may compound a drug for an identified individual patient if three core conditions are met. The substance must not be on FDA's "essentially a copy" list, it must not appear on a list of drugs withdrawn from the market for safety reasons, and if it is a bulk drug substance, it must either be on FDA's 503A Bulks List (Category 1, approved for use) or not yet have been evaluated. (3)

MOTS-c was nominated for inclusion on the 503A Bulks List. As of this writing, FDA has not placed it in Category 1 (nominated and recommended for use). Substances under active review or lacking sufficient clinical data may sit in Category 2 (nominated but not recommended) or remain in a pending state. Compounding a Category 2 substance carries legal risk because FDA may issue a warning that doing so violates the FD&C Act.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities produce larger batches without patient-specific prescriptions, but they are held to Current Good Manufacturing Practice (cGMP) standards. (4) A 503B facility may only use bulk substances on FDA's 503B Bulks List, and MOTS-c does not currently appear on that list either.

The practical takeaway: a 503B outsourcing facility cannot legally compound MOTS-c for distribution in Tennessee or any other state under current federal rules.

FDA Category 2 Designation: What It Actually Means

FDA's February 2024 update on peptide compounding clarified that several peptides, including some that had been widely compounded during the semaglutide shortage period, required closer scrutiny. While FDA's specific Category 2 guidance letters target peptides like BPC-157 and certain growth-hormone secretagogues by name, the agency's general position is that bulk substances lacking adequate safety and effectiveness data are not appropriate for compounding. (5)

MOTS-c falls into this uncertain zone. Prescribers and pharmacists who compound it without Category 1 status are operating against FDA's stated guidance, even if no enforcement action has targeted MOTS-c specifically by name as of this publication date.

Tennessee State Law: What the State Adds (and What It Doesn't)

Tennessee does not have a standalone statute that explicitly legalizes or bans MOTS-c. The state regulatory environment is built on several overlapping layers of law and rule.

Tennessee Board of Pharmacy Rules

The Tennessee Board of Pharmacy regulates compounding under Tennessee Code Annotated (TCA) Title 63, Chapter 10. Tennessee pharmacy rules generally defer to federal standards for bulk substance eligibility. A Tennessee-licensed compounding pharmacy that compounds MOTS-c without it being on the 503A Category 1 list could face Board disciplinary action for violating federal compounding standards that Tennessee has adopted by reference. (6)

Tennessee Rule 1140-03-.02 requires compounding pharmacies to comply with USP standards and applicable federal law. Because federal law currently does not support MOTS-c compounding outside a 503A pending/approved pathway, Tennessee pharmacies face the same restrictions as pharmacies in other states.

Tennessee Medical Practice Act and Prescriber Authority

Under TCA Title 63, Chapter 6, licensed Tennessee physicians have broad authority to prescribe any legally obtainable substance within the bounds of their professional judgment and standard of care. (7) A physician writing a prescription for MOTS-c is not automatically violating Tennessee law. The violation risk arises when the compounding pharmacy filling that prescription compounds a substance that lacks federal compounding authorization.

Prescribers should document medical necessity, conduct a patient-specific risk-benefit analysis, and confirm that any pharmacy they refer patients to is operating within 503A rules.

Tennessee Does Not Have a Research-Chemical Exemption

Some patients have asked whether they can obtain MOTS-c as a "research chemical" in Tennessee. They cannot legally self-administer it under this label. FDA and DEA do not recognize a general consumer research-chemical exemption for peptides. Selling MOTS-c labeled "not for human use" to individuals who intend human use is a federal violation, and purchasing it for that purpose may expose the buyer to legal risk as well. Tennessee has no state exemption that overrides this federal position.

Current Research on MOTS-c: What the Science Actually Shows

Understanding the research field helps explain why prescribers are interested in MOTS-c despite its regulatory uncertainty.

Preclinical and Early Human Data

The foundational 2015 Cell Metabolism study (Lee et al.) showed MOTS-c administration reduced obesity and improved glucose tolerance in mice on a high-fat diet, with effects mediated through the AMPK pathway. (1) A 2019 follow-up published in Nature Communications by Kim et al. Demonstrated that endogenous MOTS-c levels in humans increase with exercise, supporting the concept that it acts as a mitochondrial signal linking energy status to systemic metabolism. (8)

A 2021 study published in Aging examined MOTS-c in older adults and found that circulating MOTS-c concentrations were lower in older, less physically active individuals compared to younger controls, raising interest in exogenous supplementation as a potential strategy for age-related metabolic decline. (9)

No Phase 3 Trial Exists

No registered Phase 3 randomized controlled trial for MOTS-c appears on ClinicalTrials.gov as of 2025. Several Phase 1 safety studies have been completed or are ongoing, but without Phase 3 data, FDA approval is years away at minimum. This is the core reason MOTS-c cannot yet be a standard-of-care prescription medication in Tennessee or anywhere in the United States.

Dosing Data in Human Studies

Early human pilot data has used doses in the range of 2 mg to 10 mg administered subcutaneously, typically once or twice weekly. These dose ranges are not validated by any Phase 3 dose-finding trial. Prescribers relying on this data are working from early-phase signal data, which carries meaningful uncertainty around optimal dosing and long-term safety profiles.

How to Get MOTS-c in Tennessee: The Legitimate Pathway

Given the regulatory complexity, the only defensible pathway for a Tennessee patient to obtain MOTS-c involves the following steps. This framework was developed by the HealthRX medical team based on current FDA guidance, Tennessee Board of Pharmacy rules, and published compounding law.

Step 1: Establish Care with a Licensed Tennessee Prescriber

The prescriber must hold an active Tennessee medical license and must evaluate the patient through a legitimate patient-physician relationship. Telehealth is permitted under Tennessee law (TCA 63-1-155), provided the prescriber complies with Tennessee's telehealth prescribing standards and is registered with the Tennessee Board of Medical Examiners.

Step 2: The Prescriber Documents Medical Necessity and Performs a Risk-Benefit Analysis

Before issuing a prescription, the physician should document why MOTS-c is being considered (for example, documented metabolic dysfunction, evidence of mitochondrial insufficiency, or participation in a monitored clinical protocol), the absence of an approved alternative, and informed consent confirming the patient understands the investigational nature of the compound.

Step 3: Verify the Compounding Pharmacy's 503A Standing

The patient or prescriber should confirm that the dispensing pharmacy holds an active Tennessee pharmacy license, complies with USP 795/797 standards, and has documented a defensible position on MOTS-c's bulk substance status. A 503A pharmacy that has independently reviewed FDA's bulk substance nominations and determined MOTS-c remains in a "pending" (not Category 2 rejected) state may compound it, but this is a legally contested position. The pharmacy bears primary compliance responsibility.

Step 4: Avoid Any Source Without a Prescription

Any website, clinic, or vendor offering MOTS-c without a valid prescription from a licensed physician is operating illegally under federal law and likely in violation of Tennessee pharmacy law. This includes platforms that offer "research peptide" vials for human injection without a prescriber relationship.

Risks of Obtaining MOTS-c Outside the Legal Pathway

Purchasing MOTS-c from unregulated online vendors carries several categories of risk beyond the legal issues.

Purity and Contamination

A 2023 analysis published in JAMA Internal Medicine examined peptide products purchased from online "research chemical" vendors and found that a significant proportion contained incorrect concentrations, bacterial endotoxins, or unlabeled additives. (10) For an injected peptide, endotoxin contamination can cause fever, sepsis-like reactions, or injection-site abscesses.

No Physician Oversight

Without a prescriber, there is no mechanism for monitoring adverse effects, adjusting dosing based on laboratory markers, or identifying contraindications such as active malignancy (where AMPK-pathway peptides require caution given their effects on cellular energy metabolism).

Legal Exposure

Knowingly purchasing a non-FDA-approved substance intended for human injection from an unlicensed vendor may expose Tennessee residents to misdemeanor or felony charges under Tennessee's drug control statutes, depending on how the substance is classified at the time of purchase.

What Tennessee Patients and Prescribers Should Watch For

Regulatory status for peptides like MOTS-c shifts quickly. FDA's bulk substance review process has moved faster in 2023 to 2025 than in prior years, partly in response to the surge in peptide prescribing.

Two specific developments would change the legal field immediately. First, if FDA places MOTS-c in 503A Category 1 (recommended for use), traditional compounding pharmacies could compound it without the current legal ambiguity. Second, if FDA issues a formal Category 2 rejection letter specifically naming MOTS-c, compounding it would become clearly impermissible until an NDA is approved.

As of the publication date of this article, neither event has occurred. Prescribers should subscribe to FDA's compounding communications page for updates. (5) The Tennessee Board of Pharmacy also issues guidance letters when federal compounding rules materially change; Tennessee-licensed pharmacies should monitor Board communications at tn.gov/health.

The American Association of Clinical Endocrinology (AACE) 2023 position statement on novel peptides states: "Clinicians prescribing investigational peptides outside of formal clinical trial settings bear full responsibility for monitoring, documentation, and patient informed consent, and must be prepared to justify their clinical reasoning under applicable professional standards." (11)

Comparing MOTS-c to Other Peptides in Tennessee

Tennessee's regulatory environment for peptides broadly mirrors federal rules. For context, compare MOTS-c's status to two other frequently requested peptides:

| Peptide | 503A Status | 503B Status | Phase 3 Data | Notes | |---|---|---|---|---| | Semaglutide | FDA-approved (Ozempic, Wegovy) | Permitted under shortage rules (ended 2025) | Yes (STEP-1 trial, N=1,961) | Compounding access now restricted post-shortage | | BPC-157 | Category 2 (not recommended) | Not listed | No | FDA sent warning letters in 2024 | | MOTS-c | Pending / no Category 1 placement | Not listed | No | Gray zone; compounding legally uncertain |

Semaglutide in the STEP-1 trial (N=1,961) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). (12) MOTS-c has no comparable large-scale human trial. The contrast illustrates exactly why FDA requires Phase 3 data before granting compounding authorization.